Claims
- 1. A compound of the general formula (I):
- 2. The compound according to claim 1 wherein X and Y represent both nitrogen and Z represents CH, forming a pyrazine derivative.
- 3. The compound according to claim 1, wherein X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative.
- 4. The compound according to claim 1, wherein formula (I) represents a 4-trifluoromethylpyridine derivative.
- 5. The compound according to claim 1 wherein Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative.
- 6. The compound according to claim 1 wherein R3 is hydrogen and R1 or R2 is selected from
- 7. The compound according to claim 1 wherein R1 or R2 is selected from
- 8. The compound according to claim 1 wherein R1 or R2 is
- 9. The compound according to claim 1, wherein R1 or R2 is selected from
- 10. The compound according to claim 1 with the general formula (II):
- 11. The compound according to claim 10 wherein R3 is hydrogen.
- 12. The compound according to claim 10 wherein R7 is selected from hydrogen, methyl or ethyl.
- 13. The compound according to claim 10 wherein R7 is methyl and where said methyl is attached to the C2-position of the piperazine ring.
- 14. The compound according to claim 10 wherein R7 is hydrogen.
- 15. The compound according to claim 1, which is selected from the group consisting of:
2-(Benzyloxy)-6-(1-piperazinyl)pyrazine, 2-[(2-Methoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-[(3-Methoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-[(3 ,5-Difluorobenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-(l -Naphthylmethoxy)-6-(1-piperazinyl)pyrazine, 2-(1-Phenylethoxy)-6-(1-piperazinyl)pyrazine, 2-[1-(3-Fluorophenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[1-(2-Methoxyphenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-(3,4-Dihydro-2H-chromen-4-yloxy)-6-(1-piperazinyl)pyrazine, 2-(2-Phenylethoxy)-6-(1-piperazinyl)pyrazine, 2-[(2-Phenoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-[2-(3-Chlorophenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(2-Methoxyphenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(3Methoxyphenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(4-Methoxyphenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(2,5-Dimethoxyphenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[(2-Phenylethyl)sulfanyl]-6-(1-piperazinyl)pyrazine, 2-[(5-Fluoro-2-methoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-[(3-Cyanobenzyl)oxy]-6-(1-piperazinyl)pyrazine, 2-[(2-Chlorobenzyl)sulfanyl]-6-(1-piperazinyl)pyrazine, 2-[2-(4-Dimethylaminophenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(1H-Indol-3-yl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-[2-(1 H-Indol-1-yl)ethoxy]-6-(1-piperazinyl)pyrazine, 4-(Benzyloxy)-2-(1-piperazinyl)pyrimidine, 4-[(2-Methoxybenzyl)oxy]-2-(1-piperazinyl)pyrimidine, 2-{[3-(Benzyloxy)benzyl]oxy}-4-(1-piperazinyl)pyrimidine, 2-Benzyl-6-(1-piperazinyl)pyrazine, 2-[(3 ,5-Dimethoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine, 1-[6-(Benzyloxy)-2-pyrazinyl]-2-methylpiperazine, 1-[6-(Benzyloxy)-2-pyrazinyl]-2-ethylpiperazine 1-[6-(Benzyloxy)-2-pyrazinyl]-trans-2,5-dimethylpiperazine. 2-[2-(2-Fluorophenyl)ethoxy]-6-(1-piperazinyl)pyrazine, 2-(2,3-Dihydro-1H-inden-1-ylmethoxy)-6-(1-piperazinyl)pyrazine 2-(4-Pbenoxybutoxy)-6-(1-piperazinyl)pyrazine. 2-[(5-Phenoxypentyl)oxy]-6-(1-piperazinyl)pyrazine. 2-[(2,5-Dimethoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine. 2-{[2-(2-Phenylethyl)benzyl]oxy}-6-(1-piperazinyl)pyrazine (2R)-1-[6-(Benzyloxy)-2-pyrazinyl]-2-methylpiperazine, 2-[2-(2,6-Difluorophenoxy)ethoxy]-6-(1-piperazinyl)pyrazine 2-[2-(2-Naphthyloxy)ethoxy]-6-(1-piperazinyl)pyrazine 2-(1-Methyl-2-phenylethoxy)-6-(1-piperazinyl)pyrazine 2-{[2-(Phenoxymethyl)benzyl]oxy}-6-(1-piperazinyl)pyrazine 2-[(5-Fluoro-2-methoxybenzyl)oxy]-6-(1-piperazinyl)pyrazine 2-[(2,5-Difluoro benzyl)oxy]-6-(1-piperazinyl) pyrazine 2-[(2-Fluorobenzyl)oxy]-6-(1-piperazinyl)pyrazine 2-(Benzo[b]thiophen-3-ylmethoxy)-6-(1-piperazinyl)pyrazine, 2-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-6-(1-piperazinyl)pyrazine, 2-[1(2,6-Difluoro-phenyl)-ethoxy]-6-(1-piperazinyl)pyrazine, 2-(2-Naphthalen-2-yl-ethoxy)-6-(1-piperazinyl)pyrazine, 2-[3-(Naphthalen-2-yloxy)-propoxy]-6-(1-piperazinyl) pyrazine, b 2-[2-(7-Methoxy-naphthalen-2-yloxy)-ethoxy]-6-(1-piperazinyl)pyrazine, 2-[5-(4-Chlorophenyl)-2-methylfuran-3-ylmethoxy]-6-(1-piperazinyl)pyrazine, 2-(1H-Indol-4-ylmethoxy)-6-(1-piperazinyl)pyrazine, and their pharmacologically acceptable salts and solvates.
- 16. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.
- 17. A method for the prophylaxis or treatment of a serotonin-related medical condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.
- 18. The method according to claim 17, wherein the medical condition is related to the 5-HT2c receptor.
- 19. The method according to claim 17 wherein the medical condition is an eating disorder.
- 20. The method according to claim 17, wherein the medical condition is obesity.
- 21. The method according to claim 17, wherein the medical condition a memory disorder.
- 22. The method according to claim 17, wherein the medical condition is a mood disorder.
- 23. The method according to claim 17, wherein the medical condition is an anxiety disorder.
- 24. The method according to claim 17, wherein the medical condition is selected from sexual dysfunctions, epilepsy and urinary disorders.
- 25. The method according to claim 17, wherein the medical condition is pain.
- 26. The method according to claim 17, wherein the medical condition is substance abuse.
- 27. The method according to claim 17, wherein the medical condition is schizophrenia.
- 28. A method of making a compound of claim 1, taking a compound of the following formula:
- 29. A method of modulating serotonin in a subject comprising administering to the subject an effective amount of a compound of claim 1.
- 30. A method of modulating 5-HT2c in a subject comprising administering to the subject an effective amount of a compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0004245-7 |
Nov 2000 |
SE |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from Swedish Patent Application No. 0004245-7, filed Nov. 20, 2000 and U.S. Provisional Patent Application Serial No. 60/253,509, filed Nov. 28, 2000. These applications are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60253509 |
Nov 2000 |
US |